Company News

Abbott Laboratories sued Johnson & Johnson's Centocor unit over an alleged patent infringement. Centocor‘s Simponi (golimumab) would compete with Abbott's Humira, a rheumatoid arthritis treatment and the company's best selling drug – at $4.5 billion in global sales for 2008 – according to a Bloomberg report. Centocor's Simponi will be marketing by Schering-Plough outside of the US.

 

AstraZeneca filed a supplemental new drug application (sNDA) with the FDA for an expanded indication on Nexium. The new indication is for gastric and duodenal ulcers stemming from low-dose aspirin use. Nexium, a heartburn drug, is currently indicated for the treatment of acid reflux disease, as well as for risk reduction in the occurrence of gastric ulcers associated with continuous non-steroidal anti-inflammatory drug therapy.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.